The emerging roles of Jab1/CSN5 in cancer

Lin Wang1, Jun-Nian Zheng2,3,4, Dong-Sheng Pei5,6,7

  • 1Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, China 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China.

Insights

C-Jun activation domain-binding protein-1 (Jab1), also known as CSN5, is an oncogenic protein promoting cancer progression. This review explores Jab1/CSN5

Area of Science:

  • Molecular Biology
  • Oncology
  • Cellular Biology

Background:

  • C-Jun activation domain-binding protein-1 (Jab1), also known as COP9 signalosome subunit 5 (CSN5), is a multifunctional protein implicated in cellular processes.
  • Jab1/CSN5 is a subunit of the constitutive photomorphogenesis 9 signalosome (CSN), involved in deneddylation and regulating ubiquitin ligases.
  • Evidence suggests Jab1/CSN5 possesses oncogenic properties, participating in cancer progression and correlating with poor prognosis.

Purpose of the Study:

  • To systematically review and assess the biological implications and research advances of Jab1/CSN5 in cancer development.
  • To elucidate the role of Jab1/CSN5 in various biological responses relevant to tumorigenesis.
  • To explore the potential of Jab1/CSN5 as a therapeutic target in cancer treatment.

Main Methods:

  • Systematic literature review and assessment.
  • Analysis of data from PubMed and Medline databases.

Main Results:

  • Jab1/CSN5 is involved in cell proliferation, apoptosis, cell cycle regulation, DNA metabolism, invasion, DNA damage and repair, and recurrence.
  • Jab1/CSN5 promotes cell transformation and tumorigenesis.
  • The specific biological implications of Jab1/CSN5 activity during cancer development require further clarification.

Conclusions:

  • Jab1/CSN5 plays a significant role in multiple biological processes critical for cancer development and progression.
  • Understanding the Jab1/CSN5 signaling pathway is crucial for its therapeutic potential.
  • Jab1/CSN5 represents a promising therapeutic target for future cancer treatments.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.9K